Robins Kaplan Practice Groups and Partners Named Finalists for Elite Trial Lawyers Award
The firm and two partners have been named finalists for The National Law Journal’s 2018 Elite Trial Lawyers award.
August 2, 2018
Robins Kaplan LLP is pleased to announce that the firm has been selected as a finalist for The National Law Journal’s 2018 Elite Trial Lawyers award in both the Antitrust and Medical Malpractice categories. In addition, partners Tara Sutton and Hollis Salzman were selected as finalists to receive the NLJ’s inaugural “Elite Women of the Plaintiff’s Bar” award.
The Elite Trial Lawyer Awards recognize U.S. attorneys and law firms that have provided cutting-edge representation and achieved major wins on behalf of plaintiffs. According to the NLJ, the finalists were selected from more than 300 submissions.
Personal Injury and Medical Malpractice
For decades, Robins Kaplan’s Personal Injury and Medical Malpractice Group has achieved remarkable results on behalf of those who have suffered an injury as a result of medical negligence/personal injury. Notably, in 2017 the group helped secure a $20.6 million jury verdict on behalf of the family of a woman who died of sepsis just days after giving birth to her first child. The case stands as the largest medical malpractice wrongful death verdict in Minnesota history. In addition, the group recently obtained a jury verdict of more than $3 million on behalf of a woman who lost an eye due to infection.
Antitrust and Trade Regulation
Robins Kaplan’s Antitrust and Trade Regulation Group has regularly taken on, and won, the biggest plaintiff-side antitrust challenges—while opposing the most powerful companies and defense firms—since its inception. The practice made its initial mark nearly two decades ago, when it secured the multibillion-dollar settlement that made it the vanguard firm in the first successful battle with Big Tobacco. Since then, the group has continued to achieve major successes, most recently in the ongoing auto parts class action, in which partial settlements to date exceed $1 billion, and in the decade-long air cargo shipping services litigation, which was resolved with total settlements in excess of $1.2 billion.
Hollis Salzman has been instrumental in achieving these successes. After finalizing the settlements for buyers of air cargo services, Salzman—co-chair of Robins Kaplan LLP’s Antitrust and Trade Regulation group, assistant managing and hiring partner of the New York office, and member of the firm’s Executive Board—went on to serve as court-appointed co-lead counsel in In re Automotive Parts Antitrust Litigation. Between the two cases, she has recovered well over $2 billion for victims of anti-competitive conduct.
Tara Sutton has repeatedly achieved victories that create a path to recovery for thousands injured by drugs and medical devices. Chair of the firm’s Mass Tort Group and a member of the Executive Board, Sutton has assumed the role of lead trial counsel in a number of nine- and ten-figure mass tort cases. In recent years, she has served as lead trial counsel in bellwether cases concerning the drugs Abilify, Chantix, and Mirapex, and spearheaded the negotiation of a $1.4 billion global settlement program resolving Stryker Rejuvenate/ABGII modular hip implant litigation and a $358 million settlement of the Benicar hypertension litigation.
The finalists for the 2018 Elite Trial Lawyers Awards will be recognized at a formal ceremony in Las Vegas on October 5, 2018, at which time winners in each category will be announced.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.